WO2009079877A1 - Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif - Google Patents

Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif Download PDF

Info

Publication number
WO2009079877A1
WO2009079877A1 PCT/CN2007/071268 CN2007071268W WO2009079877A1 WO 2009079877 A1 WO2009079877 A1 WO 2009079877A1 CN 2007071268 W CN2007071268 W CN 2007071268W WO 2009079877 A1 WO2009079877 A1 WO 2009079877A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxidative stress
skin
composition according
component
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/071268
Other languages
English (en)
Chinese (zh)
Inventor
Meg M. Sun
Hongping Yie
Zuolin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFICKER PHARMACEUTICALS Ltd
Original Assignee
PFICKER PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFICKER PHARMACEUTICALS Ltd filed Critical PFICKER PHARMACEUTICALS Ltd
Priority to PCT/CN2007/071268 priority Critical patent/WO2009079877A1/fr
Publication of WO2009079877A1 publication Critical patent/WO2009079877A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Definitions

  • the invention relates to the field of pharmacy, in particular to a compound preparation developed under the guidance of an oxidative stress interference method, which can effectively reduce skin oxidative stress, and a design and a preparation method thereof.
  • the product quickly relieves itching, reduces inflammation, and aids wound healing and is free of hormonal substances.
  • Oxidative Stress Interference Period (OSIP Theory) theory is a hypothesis that we proposed at the beginning of this century based on a large number of basic research results: Oxidative stress is the self-renewal capability of the body. The key method of the self-defense mechanism. Unrecoverable oxidative stress ultimately causes pathological changes in the body. The time zone in which oxidative stress is reduced before lesions can occur to prevent disease onset is the oxidative stress window. In short, oxidative stress is an inevitable state in the body. The longest time interval for not causing pathological damage to the body is the oxidative stress window.
  • oxidative stress interference method first determines whether elevated oxidative stress is positive or poisonous, and where oxidative stress is elevated, etc., and then determines which methods and preparations are used for interference.
  • the oxidative stress interference method is an oxidative stress against toxication. Reducing oxidative stress is to reduce or even avoid the structural modification of free radicals to important biological substances such as DNA/RNA, protein molecules, and liposome. In order to avoid the body lesions caused by the variation of these substances.
  • Providing antioxidants is only one of the means to reduce oxidative stress, and reducing oxidative stress requires determining the methods and formulations to be taken, depending on the circumstances, the specific environment and requirements.
  • Reducing oxidative stress also includes many other means such as rapid release of free radicals, providing a barrier to free radical attack that requires specific protective substances, means or preparations to prevent or reduce free radicals, and promoting free radical self-polymerization.
  • a live catalyst formulation providing an oxidizing agent to modify the oxidation state of some transition metal ions such that they do not have the ability to catalyze the formation of free radicals, or to provide an oxidizing agent to alter the oxygen transporting capacity of certain materials, and the like.
  • oxidative stress interference is different from antioxidants, although oxidants also have the ability to reduce oxidative stress.
  • divalent iron complexes are the main substances that transport molecular oxygen. When it is necessary to cut off the supply of oxygen to reduce specific areas.
  • an oxidizing agent that oxidizes divalent iron to ferric iron is a substance used to reduce oxidative stress.
  • Skin is the first line of defense for humans to protect themselves. It is most vulnerable to damage. Many skin discomforts are thought to be caused by elevated oxidative stress, such as butterfly rash, skin cancer, frostbite. Contact dermatitis, skin inflammation generally, including acne acne, porphyria, psoriasis, and the like. Skin itching is a common symptom of most skin lesions. Hormones such as hydrocortisone are the best known antipruritic substances, but after long-term clinical use, hormones cause many serious side effects.
  • corticosteroids may cause disorder of water, salt, sugar, protein and fat metabolism; induce or aggravate infection, and reduce the body's ability to resist infection, so that the body's disease resistance is reduced, which is conducive to bacterial growth and reproduction. And diffusion; induce or aggravate ulcers, because hormones hinder tissue repair, delay tissue healing; can cause neurological symptoms such as agitation, insomnia, individual patients can induce mental illness, epilepsy patients can induce seizures; affect hypothalamic and anterior pituitary secretion of adrenal glands Corticosteroids, as well as causing rebound and withdrawal symptoms, and so on. Therefore, the development of non-hormonal antipruritic preparations that can quickly work, especially those developed by the oxidative stress interference method, which solves the most fundamental problems, has relieved human suffering. It is very important to make human life happier.
  • the present invention is directed to a compound preparation composition capable of effectively reducing skin oxidative stress, and a preparation method and use thereof.
  • the essential components of the composition of the present invention include a radical sealer, a blocker that prevents oxygen molecules from entering an area where oxidative stress is required to be reduced, and an internal oxidative stress substance such as glutathione that is strengthened inside the body.
  • a radical sealer a blocker that prevents oxygen molecules from entering an area where oxidative stress is required to be reduced
  • an internal oxidative stress substance such as glutathione that is strengthened inside the body.
  • Peroxidase GSH-Px
  • SOD superoxide dismutases
  • CAT catalases
  • active stimulants and optional capture freedom Base of antioxidants, and more.
  • the radical blocking agent is preferably used as a free radical blocking agent on the surface of the skin.
  • the free radical blocking agent which can be used on the skin surface includes, but is not limited to, acetate, formate, azide anion, and mannitol; etc.; their content in the formulation is generally from 0.01% to 10% by weight, preferably 0. The amount between l%_5wt%.
  • Interceptors that can be used to prevent oxygen molecules from entering areas where oxidative stress is desired include, but are not limited to, nitrates, copper sulfate, amyl nitrite, isobutyl nitrite, glycerin (nitroglycerin), nitrobenzene, aminophenol, p-amino salicyclic acid, acetaminophen, celecoxib, cyclophosphamide ), benzocaine, lidocaine, prilocaine, phenazopyridine, cinchocaine, and the like. They are generally included in the formulation in an amount of from 0.01% to 30% by weight, preferably from 0.1% to 20% by weight.
  • Activators that can be used on the surface of the skin to strengthen the activity of oxidative stress substances inside including but not limited to vitamins (, vitamin E, vitamin A, folic acid, lipoic acid, L-carnitine, selenium, zinc, glutathione Peptides, etc., their content in the formulation is generally from 0.01% to 10% by weight, preferably from 0.1% to 3% by weight.
  • the selenium or zinc species may be their inorganic compounds, such as selenite. , oxides, etc., may also be their organic complexes, such as selenoamino acids, amino acid selenium selenium, yeast selenium, zinc pyrithione, zinc-containing enzymes, and the like.
  • the free radical scavenging antioxidant is preferably used to capture free radicals on the surface of the skin.
  • Free radical-trapping antioxidants that can be applied to the skin surface include, but are not limited to, Uric Acid, Coenzyme Q, Beta Carotene, Melanin, Long-chain Unsaturated Fatty Acids or Esters, Plant-derived Phenolics (Phen 0 li cs ), malic acid, and so on.
  • the free radical-trapping antioxidant on the skin surface is present in the formulation in an amount of from 0 to 10% by weight, preferably from 0.001% by weight to 10% by weight, more preferably from 0.01% by weight to 5% by weight.
  • the composition disclosed in the present invention Since the surface damage of the skin is often accompanied by inflammation, the composition disclosed in the present invention has been found to have a good anti-inflammatory effect, which may be because inflammation is also a process of free radical poisoning. Therefore, in addition to being a good antipruritic agent, the composition disclosed in the present invention is also an excellent preparation for treating skin discomfort such as erythema, swelling, white plate, scratch, and burn.
  • Another use of the present invention is to prepare a topical bactericide which is enduring oxidative stress on human epidermis due to its oxidative stress resistance, but is fatal to pathogenic viruses.
  • the term "containing” or “including” includes “comprising”, “consisting essentially of”, and “consisting of”.
  • the term "consisting essentially of” means that in the composition, in addition to containing the essential ingredients or essential components, minor amounts and/or impurities which do not affect the active ingredient may be contained.
  • a fragrance may be included to improve the odor, as well as other additives commonly used in the art.
  • the term "pharmaceutically acceptable carrier” refers to the carrier used, including various excipients and diluents.
  • the term refers to carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J. 1991).
  • the pharmaceutically acceptable carrier in the composition may contain a liquid such as water, saline, glycerol and ethanol.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like may also be present in these carriers.
  • essential component refers to the necessary chemical as an active ingredient, ie, a free radical blocker, an oxygen barrier molecule that blocks the entry of an oxidative stress-reducing region, and an enhanced internal anti-oxidative kinase activity. Agents, and antioxidants that capture free radicals, and more.
  • the term "combination formulation” refers to a dosage form required to prepare a composition of the present invention for single use, including but not limited to lotion, cream, ointment, for ease of use. (ointment), gel (gel), spray (spray), water diffuser (emulsion), etc.
  • compositions of the present invention may also be prepared in a variety of solid dosage forms for use in the anorectal and vagina, such as tablets, pills, capsules, sustained release agents, and the like, in the case of particular need.
  • formulation refers to all components that make up the final product, including the name and The amount of the body, the sum of all the amounts is 100%.
  • the present invention comprises, in addition to the above-mentioned active ingredients, a pharmaceutically acceptable matrix carrier.
  • the matrix carrier is not particularly limited as long as it does not limit the object of the invention. Its composition is detailed as follows:
  • the present invention as an excipient includes the following: a foam thickener, a water absorbing humectant, a skin softener, a diffusing agent, and the like, and may further contain a bactericide, a preservative, a fragrance, a pigment, and the like;
  • the product is prepared as a liquid dosage form, and may then include a diluent, including but not limited to purified water; if the product of the present invention is prepared as a solid dosage form, corn starch may also be included as a filler and disintegrant; Cellulose gel and pregelatinized starch as plasticizer [J and mouth adhesive; gelatin (Gelatin) as emulsifier, binder and disintegrant; glycerin (Glycerin) as flavoring ; hydroxypropyl cellulose (hydroxypropyl eel lulose) as a water-dispersible material; magnesium stearate or zinc (magnesium / zinc stearate), talc (
  • the various dosage forms in the present invention can be produced by various existing production techniques.
  • the production process can be simply described as determining the solubility of various components in an organic solvent and water, and separately preparing the oil.
  • the phase mixture is mixed with the aqueous phase, and then the two phases are uniformly mixed at a certain temperature.
  • the ingredients in the formulation can be carried out by the following method: First, the oil phase is prepared, and the oil phase contains ethoxydiglycol, coenzyme Q10, natural fatty alcohol, vitamin E.
  • Acetate, vitamin A palmitate, clotrimazole, benzocaine, etc. stir at a temperature of 60 ° C; and the main components in the aqueous phase are pure water, aloe extract, watermelon Flavor, glutathione, hydroxyethyl ester, sodium selenite, benzalkonium chloride, glycerin, zinc pyrithione, etc., are dissolved by stirring at a temperature of 80 °C. Finally, in a vacuum emulsified pot, stir and mix well, add zinc oxide, stir and mix evenly, and cool. After filling the package.
  • the compound preparation of the present invention has also been found to have a special phenomenon that the treatment effect of the oil-in-water (0 i 1 - i n-wat er ) dosage form is significantly superior to that of the water-in-oil (wat er-) when prepared as a plaster product.
  • the non-solid dosage form product disclosed in the present invention is preferably an oil-in-water (0 i 1 - i n-wat er ) dosage form.
  • the formulations provided by the present invention are useful as skin oxidative stress inhibitors or as a medicament for the preparation or prevention of oxidative stress in the skin.
  • the compound preparation provided by the invention can effectively reduce oxidative stress of the skin
  • the compound preparation provided by the invention can effectively improve the sub-health state of the skin
  • the compound preparation provided by the invention can effectively prevent and assist in treating skin diseases
  • the compound preparation provided by the present invention does not contain a hormone.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are merely illustrative of the invention and are not intended to limit the scope of the invention.
  • the experimental methods in the following examples which do not specify the specific conditions are usually in accordance with conventional conditions or in accordance with the conditions recommended by the manufacturer. All percentages and parts are by weight unless otherwise stated.
  • Zinc pyrithione (component C) 0.80% 1.00% 1.00%
  • Zinc oxide (component C) 3.70% 3.70% 3.70%
  • aqueous phase using pure water as solvent, add aloe extract, watermelon flavor, glutathione, hydroxyethyl ester, sodium selenite, benzene to the water at a temperature of 80 ° C. Chloroammonium chloride, glycerin, zinc pyrithione, etc., stirred and dissolved for use;
  • Emulsified mixing In a vacuum emulsified pot, under the condition of 60 ° C, stir and mix well, add zinc oxide, stir and mix well, and cool;
  • Example 1 The cream prepared in Example 1 was used for animal testing to test the effects of the three formulations on skin oxidative stress.
  • Animals use a four-week-old, hairless rat that is housed in a standard animal test environment. Water and food are readily available. It is divided into six groups of six test mice. The first group was a blank group, and no X-rays were irradiated; the other groups of rats used whole body irradiation with 50 Gy X-rays to increase their oxidative stress levels, and the second and third groups were irradiated with X-rays, but did not apply the present invention.
  • the paste of the fourth group is applied immediately after the X-ray irradiation; the second group is applied with the formula 2 immediately after the X-ray irradiation; the sixth group is applied with the formula three paste immediately after the X-ray irradiation.
  • Agent The skin tissue of the test rats was sampled 36 and 72 hours after X-ray irradiation. The sampling area was about one-third of the irradiation area, and each sample was about 50 mg. The sample was immediately frozen in liquid nitrogen at -80 °C. save.
  • the oxidative stress level of the test rats was determined by the malondial dehyde (MDA) content of lipid oxidation in skin samples.
  • MDA malondial dehyde
  • the method was determined by the method of thiobarbituric acid active substance [TBARS, Analytical Biochemistry (Anal. Biochem. ) 1979, 95, 351-358], measuring the absorbance of the organic phase at 532 nm. The measured values are shown in Table 2 above.
  • a clinical trial was conducted using the cream prepared in Formulation 2 of Example 1, for a total of 20 people, with an age range of 28-45 years, 14 males, and 6 females.
  • the standard of extraction was that the local surface of the body was uncomfortable, but no healthy person was detected.
  • Appropriate amount is applied to the itching area, 12 of them no longer feel itching after 5 minutes, 5 people no longer feel itching after 15 minutes, 3 people no longer feel itching after 30 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne la préparation de composés destinés à efficacement réduire les lésions dues au stress oxydatif, qui comprennent un désactivateur des radicaux libres, un agent bloquant destiné à empêcher les molécules d'oxygène d'entrer dans la région où il est nécessaire de réduire le stress oxydatif, un stimulateur destiné à renforcer l'activité des composés anti-stress oxydatif, et un antioxydant destiné à piéger les radicaux libres. La préparation peut être sous une forme posologique solide ou sous forme d'onguent, de préférence une crème E/H. La présente invention concerne également l'utilisation de la préparation pour la fabrication d'un médicament destiné à empêcher ou à traiter le stress oxydatif.
PCT/CN2007/071268 2007-12-19 2007-12-19 Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif Ceased WO2009079877A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/071268 WO2009079877A1 (fr) 2007-12-19 2007-12-19 Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/071268 WO2009079877A1 (fr) 2007-12-19 2007-12-19 Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif

Publications (1)

Publication Number Publication Date
WO2009079877A1 true WO2009079877A1 (fr) 2009-07-02

Family

ID=40800696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/071268 Ceased WO2009079877A1 (fr) 2007-12-19 2007-12-19 Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif

Country Status (1)

Country Link
WO (1) WO2009079877A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068028A (ja) * 2003-08-28 2005-03-17 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP2005343891A (ja) * 2004-05-07 2005-12-15 Rohto Pharmaceut Co Ltd 皮膚外用剤
CN1927383A (zh) * 2006-09-14 2007-03-14 淮北市辉克药业有限公司 迅速降低氧化应激的复方制剂及其制备方法
CN101199850A (zh) * 2007-12-19 2008-06-18 淮北市辉克药业有限公司 氧化应激窗口期干扰法的皮肤复方制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068028A (ja) * 2003-08-28 2005-03-17 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP2005343891A (ja) * 2004-05-07 2005-12-15 Rohto Pharmaceut Co Ltd 皮膚外用剤
CN1927383A (zh) * 2006-09-14 2007-03-14 淮北市辉克药业有限公司 迅速降低氧化应激的复方制剂及其制备方法
CN101199850A (zh) * 2007-12-19 2008-06-18 淮北市辉克药业有限公司 氧化应激窗口期干扰法的皮肤复方制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2005-324667, THOMSON *
DATABASE WPI Derwent World Patents Index; AN 2006-071943, THOMSON *
YANG G. ET AL.: "Oxidative stress and wound healing.", JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH., vol. 11, no. 2, 14 January 2007 (2007-01-14), pages 355 - 358 *

Similar Documents

Publication Publication Date Title
EP2441454B1 (fr) Utilisation de composés isothiocyanates pour le traitement de la prostatite
CN101977596A (zh) 大麻素类的新用途
JP2017019864A (ja) 寿命を拡大させ、かつ加齢関連疾患の発症を遅らせるための方法
Chen et al. Tanshinone IIA exerts neuroprotective effects on hippocampus-dependent cognitive impairments in diabetic rats by attenuating ER stress-induced apoptosis
JPS63502437A (ja) 酸素化コレステロ−ル含有組成物および疾患の局所的処置のためのその用途
Rezabek et al. Superficial fungal infections of the skin: Diagnosis and current treatment recommendations
JPS6330884B2 (fr)
BG65847B1 (bg) Приложение на производни на бигуанидина за получаване на лекарствено средство с цикатризиращ ефект
CN106806368A (zh) 一种外用抗真菌药物组合物
TW201236677A (en) Composition for topical use for treating skin disorders
CN113101289A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
CN1972708A (zh) 用于局部治疗的组合物
EP2907513A1 (fr) Compositions comprenant de la dihydroquercetine pour utilisation dans des méthodes pour soulager les effets associés à des maladies inflammatoires de la peau
TWI294286B (en) Stabilised topical formulations containing ketoprofen
KR101072175B1 (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
TWI903311B (zh) 局部藥物組合物、其製備方法及其在醫藥上的用途
WO2025156601A1 (fr) Utilisation de la liquiritine dans la préparation d'un médicament pour traiter la dermatite atopique
CN101199850B (zh) 氧化应激窗口期干扰法的皮肤复方制剂
WO2009079877A1 (fr) Préparation d'un composé dermatologique pour la période d'interférence du stress oxydatif
JP2025510868A (ja) ミラベグロン製剤
US20190117559A1 (en) Method of treating inflammation and promoting wound healing
JPH06239757A (ja) 抗アレルギー剤
JPH09176014A (ja) 抗真菌性外用組成物
WO2007086582A1 (fr) LOTION EN ÉMULSION DE TYPE HUILE DANS L'EAU CONTENANT DE LA 22-OXA-1α,25-DIHYDROXYVITAMINE D3 ET MÉTHODE DE TRAITEMENT D'UNE MALADIE CUTANÉE UTILISANT LADITE LOTION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07846094

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07846094

Country of ref document: EP

Kind code of ref document: A1